<DOC>
	<DOCNO>NCT00622349</DOCNO>
	<brief_summary>The purpose study determine cisplatin-based chemotherapy , cisplatin-gemcitabine-ifosfamide cisplatin-docetaxel , improve survival comparison combination gemcitabine-ifosfamide patient advance NSCLC</brief_summary>
	<brief_title>Randomised Study Comparing Three Chemotherapy Regimens Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Histological cytological diagnosis nonsmall cell lung cancer Advanced ( unresectable functionally inoperable ) stage III stage IV disease Availability participate detailed followup protocol Presence evaluable measurable lesion Informed consent Prior treatment chemotherapy Operable patient resectable tumour Performance status &lt; 60 Karnofsky scale A history prior malignant tumour , except nonmelanoma skin cancer situ carcinoma cervix cure malignant tumour ( 5year disease free interval ) Polynuclear cell &lt; 2,000/mm³ Platelet cell &lt; 100,000/mm³ Serum bilirubin &gt; 1.5 mg/100 ml Serum creatinine &gt; 1.5 mg/100 ml and/or creatinine clearance &lt; 60 ml/min Perception hypoacousia Peripheral neuropathy Recent myocardial infarction ( le 3 month prior date diagnosis ) Congestive cardiac failure require medical therapy uncontrolled cardiac arrhythmia Uncontrolled infectious disease Serious medical psychological factor may prevent adherence treatment schedule</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Randomised phase III</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Advanced non-small cell lung carcinoma</keyword>
</DOC>